Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?
Trending
- Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?
- TWF1 inhibition overcomes cisplatin resistance in NSCLC by inducing ferroptosis via p53-dependent SLC7A11 repression and autophagy-mediated glutathione metabolism reprogramming
- PGC1α-mediated upregulation of PHD2 represses HIF-signaling, limiting prostate cancer progression
- New NHS cancer drug Enhertu is ‘bittersweet’ for Crawley widower
- ESR1-Directed Treatment Options in HR+/HER2− mBC
- Differentiating Mutagenesis From Genotoxic Risk in Secondary Malignancies
- Navigating Transplant Strategy for Partial Responders in T-Cell Lymphoma
- CRISPR/Cas9 screening revealed BIRC6-AS1/BIRC6 mediates abiraterone resistance via NHEJ pathway-dependent A20 degradation in prostate cancer

